• 1
    Labrie F, Bélanger A, Luu-The V et al. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev 2005; 26: 36179
  • 2
    Van Poppel H. Evaluation of degarelix in the management of prostate cancer. Cancer Manag Res 2010; 2: 3952
  • 3
    Sugiono M, Winkler MH, Okeke AA, Benney M, Gillatt DA. Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer–a pilot study. Prostate Cancer Prostatic Dis 2005; 8: 914
  • 4
    Gittelman M, Pommerville PJ, Persson BE, Jensen JK, Olesen TK, Degarelix Study Group. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol 2008; 180: 198692
  • 5
    Hamilton W, Sharp D. Symptomatic diagnosis of prostate cancer in primary care: a structured review. Br J Gen Pract 2004; 54: 61721
  • 6
    Guess HA. Benign prostatic hyperplasia and prostate cancer. Epidemiol Rev 2001; 23: 1528
  • 7
    Andersson SO, Rashidkhani B, Karlberg L, Wolk A, Johansson JE. Prevalence of lower urinary tract symptoms in men aged 45–79 years: a population-based study of 40 000 Swedish men. BJU Int 2004; 94: 32731
  • 8
    Lehrer S, Stone NN, Droller MJ, Stock RG. Association between American Urologic Association (AUA) urinary symptom score and disease stage in men with localized prostate cancer. Urol Oncol 2002; 7: 736
  • 9
    Stone NN, Marshall DT, Stone JJ, Cesaretti JA, Stock RG. Does neoadjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing prostate brachytherapy? J Urol 2010; 183: 6349
  • 10
    Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004; 46: 54754
  • 11
    Roehrborn CG, Siami P, Barkin J et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008; 179: 61621; discussion 621
  • 12
    Barry MJ, Williford WO, Chang Y et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995; 154: 17704
  • 13
    Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association. Med Care 1995; 33 (Suppl.): AS14555
  • 14
    Gleave ME, Goldenberg SL, Chin JL et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001; 166: 5006; discussion 506-
  • 15
    Langenhuijsen JF, van Lin EN, Hoffmann AL et al. Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy. Urol Oncol 2011; 29: 527
  • 16
    Ebara S, Manabe D, Kobayashi Y et al. The efficacy of neoadjuvant androgen deprivation therapy as a prostate volume reduction before brachytherapy for clinically localized prostate cancer. Acta Med Okayama 2007; 61: 33540
  • 17
    Sanghani MV, Schultz D, Tempany CM et al. Quantifying the change in endorectal magnetic resonance imaging-defined tumor volume during neoadjuvant androgen suppression therapy in patients with prostate cancer. Urology 2003; 62: 48791
  • 18
    Blank KR, Whittington R, Arjomandy B et al. Neoadjuvant androgen deprivation prior to transperineal prostate brachytherapy: smaller volumes, less morbidity. Cancer J Sci Am 1999; 5: 3703
  • 19
    Kucway R, Vicini F, Huang R, Stromberg J, Gonzalez J, Martinez A. Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J Urol 2002; 167: 24437
  • 20
    Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 43441
  • 21
    Mommsen S, Petersen L. Transurethral catheter removal after bilateral orchiectomy for prostatic carcinoma associated with acute urinary retention. Scand J Urol Nephrol 1994; 28: 4014
  • 22
    Klarskov L, Mommsen S, Klarskov P, Svoldgård N. Endocrine treatment and LUTS in men with prostate cancer. Eur Urol 2006; 5 (Suppl. 5): 250. Abstract 909
  • 23
    Klarskov LL, Klarskov P, Mommsen S, Svolgaard N. Effect of endocrine treatment on voiding and prostate size in men with prostate cancer: a long-term prospective study. Scand J Urol Nephrol 2012; 46: 3743
  • 24
    Oesterling JE. LHRH agonists: a nonsurgical treatment of benign prostate hyperplasia. J Androl 1991; 12: 3818
  • 25
    Russo A, Castiglione F, Salonia A et al. Effects of the gonadotropin-releasing hormone antagonist ganirelix on normal micturition and prostaglandin E(2)-induced detrusor overactivity in conscious female rats. Eur Urol 2011; 59: 86874
  • 26
    Bono AV, Salvadore M, Celato N. Gonadotropin-releasing hormone receptors in prostate tissue. Anal Quant Cytol Histol 2002; 24: 2217
  • 27
    Bahk JY, Kim MO, Park MS et al. Gonadotropin-releasing hormone (GnRH) and GnRH receptor in bladder cancer epithelia and GnRH effect on bladder cancer cell proliferation. Urol Int 2008; 80: 4318
  • 28
    Tanriverdi F, Gonzalez-Martinez D, Hu Y, Kelestimur F, Bouloux PM. GnRH-I and GnRH-II have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin-2 receptor gamma-chain mRNA expression in healthy males. Clin Exp Immunol 2005; 142: 10310
  • 29
    Gandaglia G, Benigni F, La Croce G et al. Degarelix reduces urodynamic changes in a rat model for experimental detrusor overactivity and produces more efficient voiding. J Urol 2011; 185: e322
  • 30
    Rick FG, Schally AV, Block NL et al. LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate 2011; 71: 73647
  • 31
    Siejka A, Schally AV, Block NL, Barabutis N. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. BJU Int 2010; 106: 13828
  • 32
    Giuliano F, Behr-Roussel D, Oger S et al. Ozarelix, an LHRH antagonist, exerts a direct relaxing effect on human prostate in vitro. J Urol 2009; 181: 693